Q-omics provides the consensus-scored SNORA70F profile across patient tissues and cancer cell-line models. SNORA70F expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNORA70F is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SNORA70F RNA expression shows 14,246 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where SNORA70F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA70F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA70F survival associations across molecular data types. SNORA70F RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA70F RNA expression–survival associations across cancer types. High SNORA70F expression shows unfavorable associations in COAD, DLBC and UCEC, but favorable associations in ACC, LUAD and UVM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for SNORA70F RNA expression.
This table summarizes SNORA70F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA70F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA70F shows lower tumor expression in KIRC, KICH, THCA, BRCA and KIRP and higher tumor expression in READ. The KIRC box plot shows higher SNORA70F RNA expression in normal versus tumor tissue (log2 FC = −1.359, t-test p < 0.001).
This table shows molecular features associated with SNORA70F in patient tissues and cancer cell lines. In patient samples, SNORA70F shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
